Ovarian neoplasms in patients with colorectal cancer: Understanding the role of prophylactic oophorectomy

Clinical Colorectal Cancer

Volumn 3, Issue 4, 2004, Pages 215-222

  Hanna, Nader N ^a,b   Cohen, Alfred M ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

^b UNIVERSITY OF KENTUCKY MEDICAL CENTER   (United States)

Author keywords

Estrogen; Hereditary nonpolyposis colorectal cancer; Pathologic features; Surgery

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; CANCER VACCINE; CYCLOPHOSPHAMIDE DERIVATIVE; ESTROGEN RECEPTOR BETA; FENRETINIDE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; ORAL CONTRACEPTIVE AGENT; OXALIPLATIN; RETINOL DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER RISK; CANCER SURVIVAL; CHEMOSENSITIVITY; CLINICAL FEATURE; CLINICAL TRIAL; COLON CARCINOGENESIS; COLORECTAL CANCER; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; GENETIC RISK; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; HYPERTHERMIC THERAPY; OUTCOMES RESEARCH; OVARIECTOMY; OVARY CANCER; OVARY METASTASIS; PATIENT SELECTION; POSTMENOPAUSE; PREMENOPAUSE; REVIEW; SIDE EFFECT; SYMPTOMATOLOGY;

EID: 1842608851     PISSN: 15330028     EISSN: None     Source Type: Journal    
DOI: 10.3816/CCC.2004.n.002     Document Type: Review

References (99)

1. American Cancer Society. Cancer Facts and Figures 2004. Atlanta, GA: ACS, 2004.
2. Webb MJ, Decker DG, Mussey E. Cancer metastatic to the ovary: factor influencing survival. Obstet Gynecol 1975; 45:391-396.
3. Israel SL, Helsel EV Jr, Hausman DH. The challenge of metastatic ovarian carcinoma. Am J Obstet Gynecol 1965; 93:1094-1101.
4. Demopoulos RI, Touger L, Dubin N. Secondary ovarian carcinoma: A clinical and pathological evaluation. Int J Gynecol Pathol 1987; 61:166-175.
5. Burt C. Carcinoma of the ovaries secondary to cancer of the colon and rectum. Dis of Colon Rectum 1960; 3:352-357.
6. Deddish M. Surgical procedures for carcinoma of the colon and rectum, with five-year end results following abdominopelvicdissection of lymph noded. American Journal of Surgery 1960; 99:188-191.
7. Barr S, Valiete M, Bacon H. Rational for bilateral oophorectomy concomitant with resection of carcinoma of the rectum and colon. Dis Colon Rectum 1962; 5:450-452.
8. Sherman L. Tenner R, Chadbourn W.A. Prophylactic oophorectomy with carcinoma of the rectum and colon. Dis Colon Rectum 1964; 7:517-520.
9. Harcourt KI Dennis D. Laparotomy for "oVarian tumors" in unsuspected carcinoma of the colon. Cancer 1968; 21:1244-1260.
10. Antoniades K, Spector HB, Hecksher RH Jr. Prophylactic oophorectomy in conjunction with large-bowl resection for cancer: Report of two cases. Dis Colon Rectum 1977; 20:506-510.
11. MacKeigan JM, Ferguson JA. Prohylactic oophorectomy and colorectal cancer in premenopausal patients. Dis Colon Rectum 1979; 22:401-405.
12. Blamey S, McDermott F, Pihl E, et al. Ovarian involvement in adenocarcinoma of the colon and rectum. Surg Gynecol Obstet 1981; 153:42-44.
13. O'Brien PH, Newton BB, Metcalf JS, et al. Oophorectomy in women with carcinoma of the colon and rectum. Surg Gynecol Obstet 1981; 153:827-830.
14. Cutait R, Lesser ML, Enker WE. Prohylactic oophorectomy in surgery for large-bowel cancer. Dis Colon Rectum 1983; 26:6-11.
15. Morrow M, Enker WE. Late ovarian metastases in carcinoma of the colon and rectum. Arch Surg 1984; 119:1385-1388.
16. Koves I, Vamosi-Nagy I, Besznyak I. Ovarian metastases of colorectal tumours. Eur J Surg Oncol 1993; 19:633-635.
17. Perdomo JA, Hizuta A, Iwagaki H, et al. Ovarian metastasis in patients with colorectal carcinoma. Acta Med Okayama 1994; 48:43-46.
18. Buirge R. Carcinoma of the large intestine: Review of four hundred and sixteen autopsy records. Arch Surg 1941; 42;801-818.
19. Abrams H, Spiro R, Goldestien M. Metastasis in carcinoma; analysis of 100 autopsied cases. Cancer 1950; 3:74-85.
20. Abu-Rustum N, Barakat RR, Curtin JP. Ovarian and uterine disease in women with colorectal cancer. Obstet Gynecol 1997; 89:85-87.
21. Tunca JC, Starling JR, Hafez GR, et al. Colon carcinoma metastatic to the ovary. J Surg Oncol 1983; 23:269-272.
22. Blamey SL, McDermott FT, Pihl E, et al. Resected ovarian recurrence from colorectal adenocarcinoma: A study of 13 cases. Dis Colon Rectum 1981; 24:272-275.
23. Herrera LO, Ledesma EJ, Natarajan N, et al. Metachronous ovarian metastases from adenocarcinoma of the colon and rectum. Surg Gynecol Obstet 1982; 154:531-533.
24. Herrera-Ornelas L, Natarajan N, Tsukada Y, et al. Adenocarcinoma of the colon masquerading as primary ovarian neoplasia. An analysis of ten cases. Dis Colon Rectum 1983; 26:377-380.
25. Mazur MT, Hsueh S, Gersell DJ. Metastases to the female genital tract. Analysis of 325 cases. Cancer 1984; 53:1978-1984.
26. Mata JM, Inaraja L, Rams A, et al. CT findings in metastatic ovarian tumors from gastrointestinal tract neoplasms (Krukenberg tumors). Gatrointest Radiol 1988; 13:242-246.
27. Loy TS, Calaluce RD, Keeney GL. Cytokeratin immunostaining in differentiating primary ovarian carcinoma from metastatic colonic adenocarcinoma. Mod Pathol 1996; 9:1040-1044.
28. Rayson D, Bouttell E, Whiston F, et al. Outcome after ovarian/adnexal metastectomy in metastatic colorectal carcinoma. J Surg Oncol 2000; 75:186-192.
29. Young-Fadok TM, Wolff BG, Nivatvongs S, et al. Prophylactic oophorectomy in colorectal carcinoma: Preliminary results of a randomized, prospective trial. Dis Colon Rectum 1998; 41:277-283.
30. Birnkrant A, Sampson J, Sugarbaker PJ. Ovarian metastasis from colorectal cancer. Dis Colon Rectum 1986; 29:767-771.
31. Burt C. Prophylactic oophorectomy with resection of the large bowel for cancer. Am J Surg 1951; 82:571-576.
32. Stearns MJ. Five-years results of abdominopelivc lymph node dissection for carcinoma of the rectum. Dis Colon Rectum 1959; 2:169-172.
33. Graffner HO, Alm PO, Oscarson JE. Prophylactic oophorectomy in colorectal carcinoma. Am J Surg 1983; 146:233-235.
34. Lindner V, Gasser B, Debbiche A, et al. [Ovarian metastasis of colorectal adenocarcinomas. A clinico-pathological study of 41 cases]. Ann Pathol 1999; 19:492-498.
35. DeCostanzo DC, Elias JM, Chumas JC. Necrosis in 84 ovarian carcinomas: A morphologic study of primary versus metastatic colonic carcinoma with selective immunohistochemical analysis of cytokeratin subtypes and carcinoembryonic antigen. Int J Gynecol Pathol 1997; 16:245-249.
36. Young RH, Hart WR. Metastatic intestinal carcinomas simulating primary ovarian clear cell carcinoma and secretory endometrioid carcinoma: Clinicopathologic and immunohistochemical study of five cases. Am J Surg Pathol 1998; 22:805-815.
37. Wauters CC, Smedts F, Gerrits LG, et al. Keratins 7 and 20 as diagnostic markers of carcinomas metastatic to the ovary. Hum Pathol 1995; 26:852-855.
38. Dionigi A, Facco C, Tibiletti MG, et al. Ovarian metastases from colorectal carcinoma. Clinicopathologic profile, immunophenotype, and karyotype analysis. Am J Clin Pathol 2000; 114:111-122.
39. Holtz F, Hart WR. Krukenberg tumors of the ovary: A clinico-pathologic analysis of 27 cases. Cancer 1982; 50:2438-2447.
40. Thomas R, Barnhill D, Worsham F, et al. Krukenberg tumor of the ovary from an occult appendiceal primary: Case report and literature review. Obstet Gynecol 1985; 65:95S-98S.
41. Gilliland R, Gill PJ. Incidence and prognosis of Krukenberg tumour in Northern Ireland. Br J Surg 1992; 79:1364-1366.
42. Watson P, Lynch HT. Extracolonic cancer in hereditary nonpolyposis colorectal cancer. Cancer 1993; 71:677-685.
43. Watson P. Vasen HF, Mecklin JP, et al. The risk of endometrial cancer in hereditary nonpolyposis colorectal cancer. Am J Med 1994; 96:516-520.
44. Aarnio M, Mecklin JP, Aaltonen LA, et al. Life-time risk of different cancers in hereditary non-polyposis colorectal cancer (HNPCC) syndrome. Int J Cancer 1995; 64:430-433.
45. Dunlop MG, Farrington SM, Carothers AD, et al. Cancer risk associated with germline DNA mismatch repair gene mutations. Hum Mol Genet 1997; 6:105-110.
46. Aarnio M, Sankila R, Pukkala E, et al. Cancer risk in mutation carriers of DNA-mismatch-repair genes. Int J Cancer 1999; 81:214-218.
47. Vasen HF, Wijnen JT, Menko FH, et al. Cancer risk in families with hereditary nonpolyposis colorectal cancer diagnosed by mutation analysis. Gastroenterology 1996; 110:1020-1027.
48. Watson P, Butzow R, Lynch HT, et al. The clinical features of ovarian cancer in hereditary nonpolyposis colorectal cancer. Gynecol Oncol 2001; 82:223-228.
49. Lynch HT, de la Chapelle A. Genetic susceptibility to non-polyposis colorectal cancer. J Med Genet 1999; 36:801-818.
50. Brown GJ, St John DJ, Macrae FA, et al. Cancer risk in young women at risk of hereditary nonpolyposis colorectal cancer: Implications for gynecologic surveillance. Gynecol Oncol 2001; 80:346-349.
51. Ford D, Easton DF, Bishop DT, et al. Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Lancet 1994; 343:692-695.
52. Cancer risks in BRCA2 mutation carriers. The Breast Cancer Linkage Consortium. J Natl Cancer Inst 1999; 91:1310-1316.
53. Raigoso P, Sanz L, Vizoso F, et al. Estrogen and progesterone receptors in colorectal cancer and surrounding mucosa. Int J Biol Markers 2001; 16:262-267.
54. Cavallini A, Messa C, Pricci M, et al. Distribution of estrogen receptor subtypes, expression of their variant forms, and clinicopathological characteristics of human colorectal cancer. Dig Dis Sci 2002; 47:2720-2728.
55. Jemal A, Thomas A. Murray T, et al. Cancer statistics, 2003. CA Cancer J Clin 2003; 53:5-26.
56. Stratton JF, Pharoah P, Smith SK, et al. A systematic review and meta-analysis of family history and risk of ovarian cancer. Br J Obstet Gynaecol 1998; 105:493-499.
57. Kontoravdis A, Kalogirou D, Antoniou G, et al. Prophylactic oophorectomy in ovarian cancer prevention. Int J Gynaecol Obstet 1996; 54:257-262.
58. Rozario D, Brown I, Fung MF, et al. Is incidental prophylactic oophorectomy an acceptable means to reduce the incidence of ovarian cancer? Am J Surg 1997; 173:495-498.
59. Sightler SE, Boike GM, Estape RE, et al. Ovarian cancer in women with prior hysterectomy: A 14-year experience at the University of Miami. Obstet Gynecol 1991; 78:681-684.
60. Prentice RL, Thomas DB. On the epidemiology of oral contraceptives and disease. Adv Cancer Res 1987; 49:285-401.
61. Hankinson SE, Colditz GA, Hunter DJ, et al. A quantitative assessment of oral contraceptive use and risk of ovarian cancer. Obstet Gynecol 1992; 80:708-714.
62. Stanford JL. Oral contraceptives and neoplasia of the ovary. Contraception 1991; 43:543-556.
63. Whittemore AS, Harris R, Itnyre J. Characteristics relating to ovarian cancer risk: Collaborative analysis of 12 US case-control studies. II. Invasive epithelial ovarian cancers in white women. Collaborative Ovarian Cancer Group. Am J Epidemiol 1992; 136:1184-1203.
64. Herrera-Ornelas L, Mittelman A. Results of synchronous surgical removal of primary colorectal adenocarcinoma and ovarian metastases. Oncology 1984; 41:96-100.
65. Huang PP, Weber TK, Mendoza C, et al. Long-term survival in patients with ovarian metastases from colorectal carcinoma. Ann Surg Oncol 1998; 5:695-698.
66. Ballantyne GH, Reigel MM, Wolff BG, et al. Oophorectomy and colon cancer. Impact on survival. Ann Surg 1985; 202:209-214.
67. Sielezneff I, Salle E, Antoine K, et al. Simultaneous bilateral oophorectomy does not improve prognosis of postmenopausal women undergoing colorectal resection for cancer. Dis Colon Rectum 1997; 40:1299-1302.
68. Grundsell H, Ekman G, Gullberg B, et al. Some aspects of prophylactic oophorectomy and ovarian carcinoma. Ann Chir Gynecol 1981; 70:36-42.
69. Geary M, Geoghegan A, Foley M. Prevention of ovarian cancer: a survey of the practice of prophylactic oophorectomy by consultant gynaecologists in Ireland. Ir Med J 1997; 90:186-187.
70. McCredie M, Macfarlane GJ, Bell J, et al. Second primary cancers after cancers of the colon and rectum in New South Wales, Australia, 1972-1991. Cancer Epidemiol Biomarkers Prev 1997; 6:155-160.
71. Piver MS, Baker TR, Jishi MF, et al. Familial ovarian cancer. A report of 658 families from the Gilda Radner Familial Ovarian Cancer Registry 1981-1991. Cancer 1993; 71:582-588.
72. Tobacman JK, Greene MH, Tucker MA, et al. Intra-abdominal carcinomatosis after prophylactic oophorectomy in ovarian-cancer-prone families. Lancet 1982; 2:795-797.
73. Lynge E, Jensen OM, Carstensen B. Second cancer following cancer of the digestive system in Denmark, 1943-80. Natl Cancer Inst Monogr 1985; 68:277-308.
74. Tanaka H, Hiyama T, Hanai A, et al. Second primary cancers following colon and rectal cancer in Osaka, Japan. Jpn J Cancer Res 1991; 82:1356-1365.
75. Becker SO, Tomacruz R, Kaufman HS, et al. Gynecologic abnormalities in surgically treated women with stage II or III rectal cancer. J Am Coll Surg 2002; 194:315-323.
76. Swisher EM, Babb S, Whelan A, et al. Prophylactic oophorectomy and ovarian cancer surveillance. Patient perceptions and satisfaction. J Reprod Med 2001; 46:87-94.
77. Meiser B, Butow P, Barratt A, et al. Attitudes toward prophylactic oophorectomy and screening utilization in women at increased risk of developing hereditary breast/ovarian cancer. Gynecol Oncol 1999; 75:122-129.
78. Fry A, Rush R, Busby-Earle C, et al. Deciding about prophylactic oophorectomy: What is important to women at increased risk of ovarian cancer? Prev Med 2001; 33:578-585.
79. Saltz LB. Cox JV, Blanke C, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000; 343:905-914.
80. Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with fluorouracil compared with fluororacil alone as first-line treatment for metastatic colorectal cancer: A multicentre randomised trial. Lancet 2000; 355:1041-1047.
81. Saltz LB, Douillard JY, Pirotta N, et al. Combined analysis of two phase III randomized trials comparing irinotecan (C), fluorouracil (F), leucovorin (L) vs F alone as first-line therapy of previously untreated metastatic colorectal cancer (MCRC). Proc Am Soc Clin Oncol 2000; 19:242a (Abstract #938).
82. Sargent DJ, Niedzwiecki D, O'Connell MJ, et al. Recommendation for caution with irinotecan, fluorouracil, and leucovorin for colorectal cancer. N Engl J Med 2001; 345:144-145.
83. Bleiberg H, de Gramont A. Oxaliplatin plus 5-fluorouracil: clinical experience in patients with advanced colorectal cancer. Semin Oncol 1998; 25:32-39.
84. Giacchetti S, Perpoint B, Zidani R, et al. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 2000; 18:136-147.
85. Hochster H, Chachoua A, Speyer J, et al. Oxaliplatin with weekly bolus fluorouracil and low-dose leucovorin as first-line therapy for patients with colorectal cancer. J Clin Oncol 2003; 21:2703-2707.
86. de Gramont A, Vignoud J, Tournigand C, et al. Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer. Eur J Cancer 1997; 33:214-219.
87. Brienza S, Bensmaine MA, Soulie P, et al. Oxaliplatin added to 5-fluorouracil-based therapy (5-FU +/- FA) in the treatment of 5-FU-pretreated patients with advanced colorectal carcinoma (ACRC): results from the European compassionate-use program. Ann Oncol 1999; 10:1311-1316.
88. Andre T, Bensmaine MA, Louvet C, et al. Multicenter phase II study of bimonthly high-dose leucovorin, fluorouracil infusion, and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimen. J Clin Oncol 1999; 17:3560-3568.
89. Maindrault-Goebel F, Louvet C, Andre T, et al. Oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOL-FOX6). GERCOR. Eur J Cancer 1999; 35:1338-1342.
90. Pilati P, Mocellin S. Rossi CR, et al. Cytoreductive surgery combined with hyperthermic intraperitoneal intraoperative chemotherapy for peritoneal carcinomatosis arising from colon adenocarcinoma. Ann Surg Oncol 2003; 10:508-513.
91. Glehen O, Mithieux F, Osinsky D, et al. Surgery combined with peritonectomy procedures and intraperitoneal chemohyperthermia in abdominal cancers with peritoneal carcinomatosis: A phase II study. J Clin Oncol 2003; 21:799-806.
92. Elias D, Blot F, El Otmany A, et al. Curative treatment of peritoneal carcinomatosis arising from colorectal cancer by complete resection and intraperitoneal chemotherapy. Cancer 2001; 92:71-76.
93. Piso P, Bektas H, Werner U. et al. Improved prognosis following peritonectomy procedures and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis from appendiceal carcinoma. Eur J Surg Oncol 2001; 27:286-290.
94. Cavaliere F, Perri P, Di Filippo F, et al. Treatment of peritoneal carcinomatosis with intent to cure. J Surg Oncol 2000; 74:41-44.
95. Gilly FN, Beaujard A, Glehen O, et al. Peritonectomy combined with intraperitoneal chemohyperthermia in abdominal cancer with peritoneal carcinomatosis: Phase I-II study. Anticancer Res 1999; 19:2317-2321.
96. Shen P, Levine EA, Hall J, et al. Factors predicting survival after intraperitoneal hyperthermic chemotherapy with mitomycin C after cytoreductive surgery for patients with peritoneal carcinomatosis. Arch Surg 2003; 138:26-33.
97. Nitecki SS, Wolff BG, Schlinkert R, et al. The natural history of surgically treated primary adenocarcinoma of the appendix. Ann Surg 1994; 219:51-57.
98. Lu KH, Garber JE, Cramer DW, et al. Occult ovarian tumors in women with BRCA1 or BRCA2 mutations undergoing prophylactic oophorectomy. J Clin Oncol 2000; 18:2728-2732.
99. Rebbeck TR, Levin AM, Eisen A, et al. Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers. J Natl Cancer Inst 1999; 91:1475-1479.